|
CA3114179A1
|
|
New immunocytokines for the treatment of cancer
|
|
WO2020065408A1
|
|
Sulfomaleimide-based linkers and corresponding conjugates
|
|
AU2019306165A1
|
|
Receptor for vista
|
|
EP3735904A1
|
|
Detecting nicotine in sweat
|
|
FR3095759A1
|
|
Agrimony extract as an anti-pollution agent
|
|
EP3735991A1
|
|
Adc for a concomitant or subsequent treatment with docetaxel
|
|
FR3090385A1
|
|
Emollient composition in the form of an emulsion
|
|
CN111295191A
|
|
Treatment of schizophrenia
|
|
EP3661482A1
|
|
Composition comprising a myrtle extract and a fluorine salt for oral application
|
|
FR3080763A1
|
|
TOPICAL COMPOSITION FOR SURFACE BURNS
|
|
WO2018202687A1
|
|
Antiseptic composition combining chlorhexidine and iodine
|
|
WO2018055037A1
|
|
Use of solid polyethylene glycol formulations in the treatment of constipation
|
|
US2019307741A1
|
|
Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination
|
|
FR3063906A1
|
|
USE OF COPAIFERA OLEORESIN IN THE PATHOLOGIES OF THE PROSTATE
|
|
US2019079099A1
|
|
A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
|
|
CA3002765A1
|
|
Composition for the treatment of igf-1r expressing cancer
|
|
EP3355883A1
|
|
Trilobine and its natural analogs for use as a drug
|
|
US2019062339A1
|
|
Hemi-synthetic trilobine analogs for use as a drug
|
|
AU2016228280A1
|
|
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
|
WO2016207345A1
|
|
3-amino-pyrazin-2-yl carboxamide and 2-amino-pyridin-3-yl carboxamide derivatives as polo-like kinase 1 (plk-1) inhibitors for the treatment of cancer
|
